J&J seeks to release COVID-19 vaccine by 2021

By The Science Advisory Board staff writers

March 30, 2020 -- Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes to release a vaccine by 2021.

The lead vaccine has been developed in partnership with Janssen Pharmaceuticals and Beth Israel Deaconess Medical Center using Janssen's AdVac technology, the company said.

Johnson & Johnson plans to begin human clinical studies on the vaccine candidate by September 2020, and anticipates the first batches of it could be available for emergency use authorization from the U.S. Food and Drug Administration (FDA) in early 2021.

The company also plans to scale its manufacturing capability so it can produce more than 1 billion doses of the vaccine, it said.

The company's vaccine development efforts have been supported by the Biomedical Advanced Research and Development Authority (BARDA), a partnership that is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services.

Copyright © 2020 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.